1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: 
 Qualitative assessment of patients with brain tumors^a
Diagnostic Information End Point Reader Gadobenate Dimeglumine Preferred Gadobutrol Preferred Significance  (P Value) 3-Reader Agreement  (κ value)
Global diagnostic preference 1 46 (40.7%) 6 (5.3%) <.0001 0.524 (61.9%)
2 54 (47.4%) 7 (6.1%) <.0001 
3 49 (53.2%) 7 (6.1%) <.0001 
Lesion border delineation 1 43 (38.1%) 5 (4.4%) <.0001 0.544 (66.4%)
2 39 (34.2%) 3 (2.6%) <.0001 
3 37 (34.0%) 3 (2.6%) <.0001 
Definition of disease extent 1 18 (15.9%) 1 (0.9%) <.0001 0.414 (73.5%)
2 21 (18.4%) 3 (2.6%) <.0001 
3 20 (17.5%) 0 <.0001 
Visualization of lesion internal morphology 1 39 (34.5%) 5 (4.4%) <.0001 0.629 (73.5%)
2 35 (30.7%) 4 (3.5%) <.0001 
3 36 (31.6%) 1 (0.9%) <.0001 
Lesion contrast enhancement 1 53 (46.9%) 7 (6.2%) <.0001 0.547 (62.8%)
2 62 (54.4%) 10 (8.8%) <.0001 
3 50 (43.9%) 7 (6.1%) <.0001 


↵a Comparisons based on 113 patients for reader 1 and 114 patients for readers 2 and 3. All other comparisons were considered equal. Numbers in parentheses represent proportions of patients.